SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma’s US arm completes tender offer to acquire Dusa Pharma

21 Dec 2012 Evaluate

Sun Pharmaceutical Industries’ subsidiary - Caraco Pharmaceutical Laboratories has completed tender offer to acquire Dusa Pharmaceuticals for $8.00 per share, net to the seller thereof in cash, without interest thereon and less any applicable withholding taxes. As per the company, after the tender offer's expiration, 2,09,46,624 shares of common stock of Dusa had been validly tendered, representing nearly 82.4% of the outstanding shares of Dusa.

Caraco Pharmaceutical will move forward with a “short-form” merger under New Jersey law after exercising its top-up option under the merger agreement, and DUSA will become a wholly owned subsidiary of the company. Following the merger, DUSA's shares will cease to be traded on The NASDAQ Global Market.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×